Proteolysis in human breast and colorectal cancer

被引:79
作者
Garbett, EA [1 ]
Reed, MWR
Brown, NJ
机构
[1] N Tees Gen Hosp, Professorial Surg Unit, Stockton On Tees TS19 8PE, England
[2] Cent Sheffield Univ Hosp, Royal Hallamshire Hosp, Dept Surg & Anaesthet Sci, Sheffield S10 2JF, S Yorkshire, England
[3] Cent Sheffield Univ Hosp, Royal Hallamshire Hosp, Dept Surg, Sheffield S10 2JF, S Yorkshire, England
关键词
proteolysis; matrix metalloproteinases (MMPs); breast cancer; colorectal cancer; metastasis;
D O I
10.1038/sj.bjc.6690689
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteolysis occurs when proteinase activity exceeds inhibitor activity. Proteolysis is normally tightly regulated and is involved in cancer invasion and metastasis. The aim of this study was to compare proteolysis in breast and colorectal cancer. Proteinase and inhibitor expression were analysed in paired tumour and normal tissue samples from 43 breast and 24 colorectal cancer patients using substrate zymography, Western blotting and quenched fluorescence substrate hydrolysis. The expression of the latent forms of matrix metalloproteinase-2 (MMP-2), MMP-3 and MMP-9, urokinase plasminogen activator (uPA), tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression were observed in both tumour and normal tissue samples from breast and colorectal tissue; however, expression was greater in the tumour tissue. Expression of active MMP-2 and MMP-9 and the total MMP activity were greater in tumour compared to normal samples in both tissues (P < 0.05). The expression of all proteinases and total MMP activity was greater in colorectal tissue than breast tissue samples. Breast and colorectal cancer demonstrated different proteinase profiles, however proteolysis in both tissues was greater in tumour tissue than normal tissue. (C) 1999 Cancer Research Campaign.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 37 条
[1]  
BARAMOVA E, 1995, CELL BIOL INT, V19, P239
[2]  
BARRETT AJ, 1995, METHOD ENZYMOL, V244, P1
[3]   PROGNOSTIC VALUE OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) AND PLASMINOGEN-ACTIVATOR INHIBITORS PAI-1 AND PAI-2 IN BREAST CARCINOMAS [J].
BOUCHET, C ;
SPYRATOS, F ;
MARTIN, PM ;
HACENE, K ;
GENTILE, A ;
OGLOBINE, J .
BRITISH JOURNAL OF CANCER, 1994, 69 (02) :398-405
[4]  
Brown CJ, 1996, J CLIN PATHOL-CL MOL, V49, pM331
[5]   EXPRESSION OF ACTIVATED GELATINASE IN HUMAN INVASIVE BREAST-CARCINOMA [J].
BROWN, PD ;
BLOXIDGE, RE ;
ANDERSON, E ;
HOWELL, A .
CLINICAL & EXPERIMENTAL METASTASIS, 1993, 11 (02) :183-189
[6]   ANTIGEN LEVELS OF UROKINASE PLASMINOGEN-ACTIVATOR AND ITS RECEPTOR AT THE TUMOR-HOST INTERFACE OF COLORECTAL ADENOCARCINOMAS ARE RELATED TO TUMOR AGGRESSIVENESS [J].
BUO, L ;
MELING, GI ;
KARLSRUD, TS ;
JOHANSEN, HT ;
AASEN, AO .
HUMAN PATHOLOGY, 1995, 26 (10) :1133-1138
[7]   THE INTERACTION OF PURIFIED RABBIT BONE COLLAGENASE WITH PURIFIED RABBIT BONE METALLOPROTEINASE INHIBITOR [J].
CAWSTON, TE ;
MURPHY, G ;
MERCER, E ;
GALLOWAY, WA ;
HAZLEMAN, BL ;
REYNOLDS, JJ .
BIOCHEMICAL JOURNAL, 1983, 211 (02) :313-318
[8]  
CLAVEL C, 1992, B CANCER, V79, P261
[9]  
COCORAN ML, 1996, ENZYME PROTEIN, V49, P7
[10]   Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis [J].
Conway, JG ;
Trexler, SJ ;
Wakefield, JA ;
Marron, BE ;
Emerson, DL ;
Bickett, DM ;
Deaton, DN ;
Garrison, D ;
Elder, M ;
McElroy, A ;
Willmott, N ;
Dockerty, AJP ;
McGeehan, GM .
CLINICAL & EXPERIMENTAL METASTASIS, 1996, 14 (02) :115-124